Colgate-Palmolive (CL)
NYSE: CL
· Real-Time Price · USD
84.29
-0.78 (-0.92%)
At close: Aug 18, 2025, 3:59 PM
84.60
0.37%
After-hours: Aug 18, 2025, 05:54 PM EDT
Colgate-Palmolive Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral, Personal and Home Care Revenue | 15.62B | 15.17B | 14.25B | 14.11B | 13.59B | 13.17B | 13.16B | 13.16B | 12.93B | 13.82B | 15.02B | 15.21B | 14.93B | 14.56B |
| Oral, Personal and Home Care Revenue Growth | +2.97% | +6.41% | +1.02% | +3.84% | +3.19% | +0.09% | -0.05% | +1.79% | -6.45% | -7.99% | -1.23% | +1.90% | +2.49% | n/a |
| Pet Nutrition Revenue | 4.48B | 4.29B | 3.71B | 3.31B | 2.88B | 2.52B | 2.39B | 2.29B | 2.26B | 2.21B | 2.25B | 2.21B | 2.16B | 2.17B |
| Pet Nutrition Revenue Growth | +4.50% | +15.54% | +12.14% | +14.85% | +14.18% | +5.74% | +4.19% | +1.24% | +2.35% | -1.91% | +1.99% | +2.36% | -0.55% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.95B | 1.9B | 1.89B | 1.96B | 1.91B | 1.86B | 1.8B | 1.82B | 1.75B | 1.75B | 1.63B | 1.63B | 1.64B | 1.58B | 1.6B | 1.64B | 1.57B | 1.6B | 1.63B | 1.52B | 1.4B | 1.47B | 1.39B | 1.4B | 1.36B | 1.36B | 1.32B | 1.36B | 1.29B | 1.39B | 1.32B | 1.41B | 1.29B | 1.34B | 1.23B | 1.31B | 1.32B | 1.35B | 1.29B | 1.35B | 1.38B | 1.45B |
| Selling, General, and Administrative Revenue Growth | +3.00% | +0.21% | -3.62% | +2.77% | +2.80% | +3.11% | -0.93% | +4.00% | -0.11% | +7.29% | +0.12% | -0.79% | +4.18% | -1.25% | -2.32% | +4.34% | -2.31% | -1.71% | +7.58% | +8.82% | -4.91% | +5.24% | -0.50% | +3.09% | -0.15% | +3.18% | -3.01% | +5.43% | -6.99% | +5.16% | -6.25% | +8.90% | -3.65% | +9.47% | -6.70% | -0.53% | -2.51% | +5.29% | -4.53% | -2.46% | -4.76% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 274M | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | n/a |